Is your company considering an Rx-to-OTC switch for one of your brands? FDA's approval of two first-in-class Rx-to-OTC switches in 2013 coupled with their announcement of the Non-prescription Safe Usage Regulatory Initiative (NSURE) has increased interest in evaluating future switch candidates as part of life cycle management.  It’s important to do a thorough evaluation before starting a switch development program, including understanding the regulatory criteria, the current market potential, and learning from the performance of past switches.    Join this introductory webinar to understand the current influences that are affecting the opportunity for Rx-to-OTC switches for the OTC industry.

Seminar Information
Seminar Date:
January 15, 2014
Webinar Objectives
  • FDA's past and present view on Rx-to-OTC switch, including criteria for switch.
  • Rx-to-OTC switch case studies, observations and performance metrics of past switched products.
  • Rx-to-OTC switch market potential, factors for consideration and prospective categories including pros/cons of each category.
  • Rx-to-OTC switch factors for success.
Rx-to-OTC Switch Part 1: Making the Case for a Switch Development Program
Speaker Information
Lisa Buono  [ view bio ]
John Dent Ph.D.  [ view bio ]
Susan Lavine Coleman  [ view bio ]
David Spangler (Moderator)  [ view bio ]
Individual topic purchase: Selected
You must be logged in to access CHPA Subscriptions.
To continue, you need to log in to CHPA. If you have any questions about your account please contact us at 1-866-702-3278.
Email Address:
CHPA Member Price:$199.00
Non-Member Price:$199.00